Literature DB >> 21796274

Akt signaling is required for glioblastoma maintenance in vivo.

James P Robinson1, Matthew W Vanbrocklin, Andrea J McKinney, H Michael Gach, Sheri L Holmen.   

Abstract

Glioblastoma multiforme (GBM) can be induced in mice through the combined expression of activated forms of KRas and Akt in glial progenitor cells. We have previously demonstrated that KRas is required for the maintenance of these tumors in vivo as inhibition of KRas expression resulted in apoptotic tumor regression and significantly increased survival. To determine the reliance of these tumors on Akt signaling in vivo, we generated a viral vector that allows the expression of Akt to be controlled post-delivery. Survival rates were compared between those animals with continued Akt expression and animals in which expression of Akt was suppressed. Although a fifth of the tumors were refractory to treatment, inhibition of Akt significantly increased the survival of tumor-bearing mice and nearly a fourth of the mice remained in remission four months after the treatment period. These data suggest that Akt is required for glioblastoma maintenance in the context of activated Ras and that loss of Akt expression results in increased survival; therefore, the PI3K/AKT signaling pathway is a viable therapeutic target in this context.

Entities:  

Year:  2011        PMID: 21796274      PMCID: PMC3142953     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  25 in total

1.  Delivery of short hairpin RNA sequences by using a replication-competent avian retroviral vector.

Authors:  Jennifer L Bromberg-White; Craig P Webb; Veronique S Patacsil; Cindy K Miranti; Bart O Williams; Sheri L Holmen
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  Recent advances in the protein kinase B signaling pathway.

Authors:  James R Woodgett
Journal:  Curr Opin Cell Biol       Date:  2005-04       Impact factor: 8.382

Review 3.  Hypoxia signalling in cancer and approaches to enforce tumour regression.

Authors:  Jacques Pouysségur; Frédéric Dayan; Nathalie M Mazure
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Authors:  J P Robinson; M W Vanbrocklin; K J Lastwika; A J McKinney; S Brandner; S L Holmen
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

5.  Essential role for Ras signaling in glioblastoma maintenance.

Authors:  Sheri L Holmen; Bart O Williams
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

6.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice.

Authors:  A Kistner; M Gossen; F Zimmermann; J Jerecic; C Ullmer; H Lübbert; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 7.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.

Authors:  E C Holland; W P Hively; R A DePinho; H E Varmus
Journal:  Genes Dev       Date:  1998-12-01       Impact factor: 11.361

Review 9.  Biology of glioma cancer stem cells.

Authors:  Deric M Park; Jeremy N Rich
Journal:  Mol Cells       Date:  2009-07-20       Impact factor: 5.034

Review 10.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

View more
  17 in total

1.  Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Authors:  Gemma L Robinson; James P Robinson; Kristin J Lastwika; Sheri L Holmen; Matthew W Vanbrocklin
Journal:  Genes Cancer       Date:  2013-11

2.  Aplysin induces apoptosis in glioma cells through HSP90/AKT pathway.

Authors:  An-jing Gong; Li-li Gong; Wei-cheng Yao; Na Ge; Lu-xiang Lu; Hui Liang
Journal:  Exp Biol Med (Maywood)       Date:  2014-11-06

3.  MIR133A regulates cell proliferation, migration, and apoptosis by targeting SOX9 in human colorectal cancer cells.

Authors:  Santosh Lamichhane; Ji-Su Mo; Grinsun Sharma; Sun-Myoung Joung; Soo-Cheon Chae
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

4.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

Review 5.  Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Authors:  Gulten Tuncel; Rasime Kalkan
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

6.  Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

Authors:  Xi-Rui Wang; Hui Luo; Hai-Lin Li; Lei Cao; Xie-Feng Wang; Wei Yan; Ying-Yi Wang; Jun-Xia Zhang; Tao Jiang; Chun-Sheng Kang; Ning Liu; Yong-Ping You
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

7.  Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.

Authors:  Xiangyu Liu; Kangjian Sun; Handong Wang; Yuyuan Dai
Journal:  Cell Mol Neurobiol       Date:  2016-03-14       Impact factor: 5.046

8.  Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Authors:  James P Robinson; Vito W Rebecca; David A Kircher; Mark R Silvis; Inna Smalley; Geoffrey T Gibney; Kristin J Lastwika; Guo Chen; Michael A Davies; Douglas Grossman; Keiran S M Smalley; Sheri L Holmen; Matthew W VanBrocklin
Journal:  Melanoma Res       Date:  2017-12       Impact factor: 3.599

9.  Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.

Authors:  Christine Carico; Miriam Nuño; Debraj Mukherjee; Adam Elramsisy; Jocelynn Dantis; Jethro Hu; Jeremy Rudnick; John S Yu; Keith L Black; Serguei I Bannykh; Chirag G Patil
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

10.  Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.

Authors:  Caroline N Mills; Somaira Nowsheen; James A Bonner; Eddy S Yang
Journal:  Front Mol Neurosci       Date:  2011-11-25       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.